Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against HIV.
The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against HIV.
What's Your Reaction?
